ClinicalTrials.gg

Program

VIS954

A development code.

Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, led by Otsuka.

Furthest: phase 2, since Oct 23, 20264 company-led studies, 2 open or runningNext primary completion: Mar 13, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka42 open or runningphase 2since Oct 23, 2026Dec 11, 2023Mar 13, 2029phase 2 · NCT07933445

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT06212804 · 54 enrolled · United States
  2. Apr 9, 2025Phase 1 study in HealthyNCT06937593 · 24 enrolled · United States
  3. Oct 23, 2026Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPhase 2 reachedNCT07904806 · 75 planned
  4. Nov 6, 2026Phase 2 study in Inflammatory Skin DiseasesNCT07933445 · 108 planned

Ahead

  1. Mar 13, 2029Primary completion: phase 2 study in Inflammatory Skin DiseasesNCT07933445
  2. Nov 20, 2029Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07904806

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933445Inflammatory Skin Diseases2Not yet recruitingMar 13, 2029108
NCT07904806Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis2Not yet recruitingNov 20, 202975
NCT06937593Healthy · United States1CompletedFeb 3, 202624
NCT06212804Healthy Volunteers · United States1CompletedJul 19, 202454

How it is read

Names in the registry

  • “VIS954”, 4 entries

Codes read as this program: VIS954.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.